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similar type of post-hoc analysis in previous large trials 
(eg, SERAPHIN10). However, Hoeper and colleagues did 
not explain their rationale for including in their analysis all 
patients (ie, the modiﬁ ed intention-to-treat population), 
rather than the primary analysis set of patients who 
met the more stringent inclusion criteria for pulmonary 
arterial hypertension. One would assume that the main 
reason was to increase statistical power, since the overall 
number of deaths in the study was low. Additionally, in 
exploratory covariate analysis, the authors found that, 
surprisingly, a higher cardiac index was associated with 
increased mortality. This ﬁ nding is certainly at odds with 
previous observations that baseline haemodynamics, 
particularly low cardiac output or index, have consistently 
predicted poor long-term outcomes. Such ﬁ nding raises 
the intriguing possibility that combined vasodilator 
therapy, by causing perhaps an unsuspected deleterious 
increase in cardiac index, might confound survival results. 
Another valid concern is whether the low number of 
deaths in all three groups (either monotherapy and 
combined therapy) is a signiﬁ cant limiting factor in the 
interpretation of this post-hoc analysis. 
However, Hoeper and colleagues should be com-
plimented for their thought-provoking analysis and 
ﬁ ndings, which strongly raise the possibility that 
a radically diﬀ erent therapeutic approach (ie, up-
front combination therapy) might improve the only 
meaningful endpoint (ie, death) in this disease. Other 
questions that remain unanswered by the AMBITION 
trial are what speciﬁ c drug combination works best, and 
whether upfront combination therapy or sequential 
add-on therapy, as dictated by clinical deterioration, is 
the most appropriate approach. Hopefully, Hoeper and 
colleagues’ work will inspire investigators, industries, 
and regulatory agencies alike to ﬁ nally consider death as 
the most relevant endpoint in this disease, despite the 
obvious challenge of conducting trials of even longer 
duration to achieve this important goal. 
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 A practical tool for primary care antimicrobial stewardship 
in children
Respiratory tract infections are the single most 
important cause of consultations in primary care.1 
Approximately 60% of 0–4 year-olds and 30% of 
5–15 year-olds present with an acute respiratory 
infection at least once a year,1 positioning the 
primary care consultation for respiratory tract 
infection as a high-profile target for antimicrobial 
stewardship initiatives. However, despite national 
and international calls for more targeted use,2 
primary care prescription of antibiotics for coughs 
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and colds increased by 40% in the UK between 1999 
and 2011,3 in part reflecting the uncertainties facing 
patients, parents, and health-care professionals 
when managing these common but potentially life-
threatening infections. 
Safety assessments of no antibiotic prescription 
initiatives for respiratory tract infections will play 
an important part in gaining public acceptance and 
successful uptake in practice.4 Present evidence 
remains equivocal, suggesting that insuﬃ  ciently 
informed reduc tions in antibiotic prescription in 
primary care might increase rates of pneumonia 
diagnosis,5 hospital admissions, and even mortality.6 
Yet decreased prescribing rates have also been shown 
to have little eﬀ ect on rates of rare complications such 
as mastoiditis, empyema, meningitis, intracranial 
abscess, and Lemierre’s syndrome.5 Tools that inform 
antibiotic use according to individualised patient risk 
proﬁ les could help to realise the beneﬁ ts of antibiotic 
stewardship programmes in primary care while 
minimising potential risks.
In The Lancet Respiratory Medicine, Hay and 
colleagues7 report the results of a prognostic cohort 
study to devise a clinical prediction rule to target 
antibiotic prescribing in children with respiratory 
tract infections. The aim was to derive (and validate) a 
clinical prediction rule to improve targeted antibiotic 
prescribing in children with respiratory tract infections. 
The study included 8394 children aged 3 months to 
15 years presenting with acute cough and respiratory 
tract infection to 247 general practices in England. Risk 
of hospital admission in the month after presentation 
in primary care was assessed. Exposure variables 
included demographic characteristics, parent-reported 
symptoms, and physical examination signs. More 
than a third (3121) of the children were prescribed 
an antibiotic on the day of consultation, and 78 (1%) 
were admitted to hospital with a respiratory tract 
infection in the following 30 days. Irrespective of 
antibiotic prescription, seven characteristics were 
in dependently associated (p<0·01) with hospital 
admission. This statistical analysis underpinned the 
creation of a seven-item points-based checklist (one 
point per item) comprising characteristics easily 
assessable at the point of care: short illness duration 
(≤3 days); body temperature; age (<2 years); recession; 
wheeze; asthma; and vomiting (STARWAVe). Using 
the STARWAVe mnemonic to help structure point-of-
care assessment of children presenting with cough 
and respiratory tract infection should predict the risk 
of hospital admission with remarkable accuracy (area 
under the received operating characteristic curve 0·81, 
95%CI 0·76–0·85). 
Because the statistical model used to produce the 
STARWAVe checklist included children prescribed 
antibiotics (37% of the total study population), 
it does not reflect the baseline risk of hospital 
admission in patients not treated with antibiotics. 
Children with a diagnosis of asthma, who accounted 
for nearly 10% (750) of the total population, were 
also included in the study. The fact that asthma 
was the strong predictor of hospital admission in 
the STARWAVe checklist despite its presence in 
only 10% of the patient population could reflect 
the magnitude of effect of comorbid obstructive 
airway disease on hospital admission for respiratory 
tract infection in this young population. Without a 
separate analysis, it is difficult to know explicitly how 
well the tool works in the majority, non-asthmatic 
subpopulation. Validation of the model was only 
feasible via statistical methods (bootstrapping) 
with the full scope of intended validation limited 
by the lower-than-expected hospital admission 
rate and a consequent lack of statistical power. 
External validation is important, because (despite 
high enrolment rates) the study population did not 
include 164 children whose parents did not consent 
to the study; consequently, the small minority 
of severely ill children might not have been fully 
represented in the study population (only 204 of 
whom had a STARWAVe score of 4–7). Yet validation 
attempts using clinical or research databases will 
be thwarted if, as seems likely, the full range of 
STARWAVe variables are not collected routinely. A 
pragmatic alternative might be a prospective pilot 
study assessing the within-practice effect of future 
versus historical outcomes (ideally compared with 
best practice comparator sites to take account of 
temporal variations in respiratory tract infection), or 
a cluster randomised trial.
Notwithstanding the inclusion of patients prescribed 
an antibiotic and the absence of an independent 
validation cohort, STARWAVe promises to achieve 
better targeting of antibiotics in primary care. There 
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are few eﬃ  cacious interventions for respiratory 
tract infection available to primary care clinicians 
beyond oﬀ ering reassurance and self-manage ment 
advice, so the modest beneﬁ t oﬀ ered by antibiotics8 
can persuade general practitioners to prescribe 
them. STARWAVe oﬀ ers primary care clinicians an 
evidence-based practical tool to help guide antibiotic 
prescription decisions and, through shared decision-
making, has the potential to reduce antibiotic 
prescription based on prognostic uncertainty or on 
non-medical grounds.9 Combining this tool with 
point-of-care C-reactive protein (CRP) testing, or to 
triage for CRP testing,10 might help to target antibiotic 
use further. 
If STARWAVe leads to an increase in antibiotic 
prescription (to 90%) in high-risk children and a 
parallel halving of prescription to those at low risk 
of hospital admission, it could achieve a 10% overall 
reduction in primary care antibiotic prescriptions for 
respiratory tract infections. Within the wider context, 
the eﬀ ect of such outcomes on the global burden of 
antimicrobial resistance will depend on the extent to 
which its emergence and spread is truly associated 
with community prescribing as opposed to antibiotic 
use in hospitals or agriculture.11
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Managing threats to respiratory health in urban slums
More than half the world’s population lives in urban 
areas, and an estimated 863 million people currently 
live in urban slums.1 Although urbanisation is usually 
coupled with economic development, rural-to-urban 
migration can result in negative implications for 
respiratory health. Slum residents who live in informal 
settlements and who commonly have inadequate 
access to health services are at a particularly high risk 
of being aﬀ ected by the dual burden of infectious 
and non-communicable respiratory diseases over the 
course of their lives. These diseases include pneumonia 
in early life; asthma beginning in childhood; and 
tuberculosis, COPD, and restrictive lung diseases 
during adulthood. Threats to respiratory health 
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